- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ASRS 2022 to Highlight Novel Therapies and Trends in Care for Retina Specialists
The American Society of Retina Specialists (ASRS) will hold its 40th Annual Scientific Meeting in New York, New York, July 13-16, 2022.
Among the sessions on novel therapies in retinal care, the latest technologies in ophthalmology, and instructional courses, the results of the Preferences and Trends (PAT) Survey and Global Trends Survey will be presented at this year’s annual meeting of the American Society of Retina Specialists (ASRS).
The 40th Annual Scientific Meeting of ASRS will be held July 13-16, 2022, in New York, New York, and virtually. Each day of the meeting will feature the latest in wet and dry age-related macular degeneration, surgery, and diabetic retinopathy.
Among the clinical presentations are results on dosing strategies with anti–vascular endothelial growth factor and the efficacy of suprachoroidal triamcinolone acetonide injectable suspension to treat macular edema.
There are also 5 late-breaking presentations:
- Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
- Phase IIIb TALON Study of Brolucizumab Versus Aflibercept in a Matched Treat-and-Extend Regimen to Treat Neovascular AMD: 32-week Primary Outcomes
- 12-Month Results of EYP-1901 Vorolanib in a Bioerodible Durasert Insert for nAMD: The DAVIO Trial
- Benefits and Value of Treatment for Diabetic Macular Edema
- Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically Induced Mydriasis in Two Pivotal Phase 3 MIRA Trials
In addition to clinical presentations, there will be a panel discussion on transformative technology and multiple presentations during a technology symposium section. The technology presentations include one on smartphone-based home vision monitoring, which is the Fellows Forum Award Winner.
On Friday, ASRS will present 9 awards, including the 2022 Founders Award, the ASRS Presidents’ Retina Young Investigators Award, and the Retina Hall of Fame Award.
Finally, the ASRS annual meeting will include the latest results of the annual PAT Survey and the Global Trends survey. These surveys review technologies being used, therapies being prescribed, what influences decisions for treatment, and more. Respondents are both based in the United States and internationally.
The ASRS meeting will close on Saturday, July 16, with poster and film awards.
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Depth of Responses, PFS in Transplant-Ineligible Patients Match Overall Findings in CEPHEUS
June 2nd 2025Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; there is debate whether all newly diagnosed patients should have this regimen.
Read More
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer
June 2nd 2025Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.
Read More
